Following a public consultation, the Medicine and Healthcare products Regulatory Agency (MHRA) is making Nuromol, a medicine that contains 200mg of ibuprofen and 500mg of paracetamol per tablet available without the need to visit a pharmacy.
The MHRA’s decision to reclassify this product follows a review by the Commission on Human Medicines (CHM) and a public consultation. The CHM advises ministers on the safety, efficacy and quality of medicinal products.
Dr Sarah Branch, Director of Vigilance and Risk Management of Medicines at the MHRA, said:
“This reclassification to general sales list will help people to manage their pain where paracetamol or ibuprofen alone have not provided adequate pain relief.
“Wider availability of medicinal products and improved patient access and choice remain high on the health agenda. The MHRA is committed to improving access to medicinal products for self-care where it is safe to do so.”